.Pharmacolibrary.Drugs.ATC.L.L01BA04

Information

Pemetrexed is a multi-targeted antifolate chemotherapeutic agent used primarily in the treatment of malignant pleural mesothelioma and non-small cell lung cancer. It inhibits several key enzymes involved in folate metabolism and DNA synthesis. Pemetrexed is an approved drug and is commonly used in combination with cisplatin.

Pharmacokinetics

Pharmacokinetic parameters are reported for adult patients with solid tumors, primarily non-small cell lung cancer, after a single intravenous infusion. The patients included both males and females with normal renal function.

References

1. Srinivasan, M, et al., & Prabhash, K (2019). Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients. Journal of clinical pharmacology 59(9) 1216–1224. DOI:10.1002/jcph.1417 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30973978

2. Ouellet, D, et al., & Lalonde, RL (2000). Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. Cancer chemotherapy and pharmacology 46(3) 227–234. DOI:10.1007/s002800000144 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11021740

3. Latz, JE, et al., & Johnson, RD (2006). Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer chemotherapy and pharmacology 57(4) 401–411. DOI:10.1007/s00280-005-0036-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16322991

Revisions

• 06/2025 initial generated model